Helical TomoTherapy for locally advanced or recurrent breast cancer

We report our experience of using helical tomotherapy (HT) to treat large and irregular shaped loco-regional advanced breast cancer target volumes embracing various organs at risk. We retrospectively analyzed 26 patients treated for very large, irregular shaped breast cancers. Patients were treated...

Full description

Saved in:
Bibliographic Details
Published in:Radiation oncology (London, England) England), 2017-01, Vol.12 (1), p.31, Article 31
Main Authors: Duma, M N, Heinrich, C, Schönknecht, C, Chizzali, B, Mayinger, M, Devecka, M, Kampfer, S, Combs, S E
Format: Article
Language:English
Subjects:
Adult
Aged
Breast cancer
Breast Neoplasms - mortality
Breast Neoplasms - radiotherapy
Care and treatment
Chemotherapy
Combined Modality Therapy
Disease-Free Survival
Female
Health aspects
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - radiotherapy
Organs at Risk
Radiotherapy
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Radiotherapy, Intensity-Modulated - methods
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report our experience of using helical tomotherapy (HT) to treat large and irregular shaped loco-regional advanced breast cancer target volumes embracing various organs at risk. We retrospectively analyzed 26 patients treated for very large, irregular shaped breast cancers. Patients were treated either with the intent to achieve local control in a primary setting (n = 14) or in a reirradiation setting (n = 12). The recurrence group was heavily pretreated with systemic therapy. Tumors were characterized by wide infiltration of the skin, encompassing mostly a complete hemithorax. The primary group underwent irradiation of supraclavicular, infraclavicular, axillary and parasternal lymphonodal region. Radiotherapy was combined with chemotherapy (n = 11). We assessed the PTV volume and its craniocaudal extension, the dose to the organs at risk, acute toxicity and survival. Median PTV was 2276 cm (1476-6837 cm ) with a median cranio-caudal extension of 28 cm (15-52 cm). The median dose to PTV was 40 Gy (32-60Gy). HT could be carried out in all patients without interruption. The acute toxicities were mild to moderate. The median LRFS and OS after radiotherapy was 21 and 57 months for the primary group versus 10 and 11 months for the recurrence group. Median PFS was 18 months (primary group) and 7 months (recurrence group). HT is feasible for advanced thorax embracing target volumes with acceptable acute toxicity. Both curative and palliative indications can be considered good indications based on treatment volume and anatomical constellation.
ISSN:1748-717X
1748-717X
DOI:10.1186/s13014-016-0736-1